前列腺癌与李-弗劳梅尼综合征：对筛查和治疗的启示
Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy.
作者信息
Spees Colleen K, Kelleher Kelly J, Abaza Ronney, Clinton Steven K
机构信息
Medical Dietetics and Health Sciences, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
College of Public Health, The Ohio State University, Columbus, OH, USA; Research Institute at Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
出版信息
Urol Case Rep. 2015 Feb 7;3(2):21-3. doi: 10.1016/j.eucr.2015.01.002. eCollection 2015 Mar.
Li-Fraumeni Syndrome (LFS) is an autosomal dominant genetic disorder associated with mutations in the TP53 gene and characterized by a propensity to develop a variety of malignancies resulting in a shortened lifespan. We report a case of prostate cancer in a 50 year old male with LFS. Experimental studies suggest that TP53 mutations in prostate cancer are associated with therapeutic resistance to radiation, chemotherapy, and anti-androgens, implying that LFS men may experience more aggressive cancer biology with implications for therapeutic decisions. The potential of prostate cancer to develop earlier in LFS favors institution of screening at earlier ages.
李-弗劳梅尼综合征（LFS）是一种常染色体显性遗传病，与TP53基因的突变有关，其特征是易患多种恶性肿瘤，导致寿命缩短。我们报告了一例50岁患有LFS的男性前列腺癌病例。实验研究表明，前列腺癌中的TP53突变与对放疗、化疗和抗雄激素治疗的耐药性有关，这意味着患有LFS的男性可能经历更具侵袭性的癌症生物学行为，对治疗决策具有重要意义。LFS患者中前列腺癌发病较早的可能性促使在更早的年龄进行筛查。
Zotero 插件